Quality of Life and Ultrasonographic Assessment of Nail Psoriasis After Treatment With Apremilast (JUST Study)

Inclusion Criteria: * Patients older than 18 years old at the time of signing the IC * Patients with the diagnosis of plaque psoriasis, moderate to severe, at least 6 months before recruitment, with nail involvement and without active psoriatic arthropathy * Nail involvement with a minimum NAPSI of 12 for fingernails, and any NAPSI for toenails * Patients naïve to biological treatments * In pregnant women, pregnancy must be ruled out before treatment can be started and they must use an effective contraceptive method to prevent pregnancy during treatment Exclusion Criteria: * Other major or clinically uncontrolled diseases * Pregnancy or breastfeeding * History of allergy to any component of the study medication * Positivity for HBV surface antigen at the screening visit * Positivity for HCV serology at the screening visit * Active tuberculosis or inadequately treated history of tuberculosis * Significant abnormalities in electrocardiogram at the screening visit * Clinically significant abnormalities of the X-ray chest at the screening visit * History of HIV infection or other acquired or congenital immunodeficiencies * Active abuse or history of substance abuse 6 months prior to the screening visit * Bacterial infection that required oral or injectable antibiotics or important viral or fungal infections within 4 weeks prior to the screening visit * Malignancy or history of malignancy (other than cured in situ cutaneous squamous cell carcinoma or basal cell carcinoma, or in situ cérvix carcinoma without evidence of recurrence in the last 5 years) * Rebound or relapse of psoriasis in the 4 weeks prior to the screening visit * Presence of other cutaneous diseases that could interfere in the clinical assessment of the study * Use of topical treatments that include corticosteroids, salicylic acid, urea\> 10% or calcipotriol in the 2 weeks prior to the screening visit * Use of systemic treatments for psoriasis, including systemic corticosteroids and PUVA or UVB phototherapy, within 4 weeks prior to the screening visit * Previous or current use of biological treatments * Use of any investigational drug within 4 weeks prior to the screening visit * Previous treatment with apremilast